FTI Consulting Survey: Majority of Private Equity Leaders Say M&A Is Not a Top Priority for 2025
WASHINGTON, June 24, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today released the 2025 Private Equity Value Creation Index, which found that M&A ranked last among 10 value creation levers, with only 9% of global private equity leaders naming it their top priority for 2025.
The survey of more than 500 global private equity decision makers highlights ways in which firms continue to over index on conventional cost levers — such as cost structure optimization, supply chain and operations — which are widely used and effectively executed, while growth strategies remain underutilized or face a clear execution gap.
At the same time, artificial intelligence ('AI') has emerged as the top strategic priority for 2025 — and the leading factor for exit readiness — signaling its growing importance in positioning portfolio companies for long-term value. Yet, it remains one of the least frequently used and most challenging levers to implement.
'Cost has become the dominant conversation,' said Jiva J. Jagtap, Global Leader of Private Equity at FTI Consulting. 'In a high-uncertainty, low-growth market, cost is often the most immediate lever for protecting value. But cost alone doesn't deliver returns. High-performing firms treat it as a catalyst, using savings to reinvest in the capabilities and growth engines that drive sustainable value creation. Growth is harder to unlock — which is exactly why it's more valuable. And while M&A has fallen as a near-term priority due to integration hurdles and valuation gaps, that very pullback may open a window of opportunity for disciplined buyers to make strategic moves.'
Additional key findings include:
Technology and IT emerged as both the most frequently used and most effective value creation lever, with 84% of respondents using it regularly and 77% rating its effectiveness as above average. Yet despite its strong track record, technology was also cited as the top execution challenge at the portfolio company level.
M&A remains a staple in the value creation toolkit, but it was rated the worst-performing value creation lever, and 67% of respondents indicated that it takes more than a year to achieve the value they expected. With deals hard to execute and slow to deliver returns, success becomes a collective effort. Portfolio company leaders, operating partners and deal teams must all play their part to ensure strong operational governance, common goals and clear communications. Any breakdown here can undermine value.
AI usage is advancing rapidly, with 42% of private equity leaders saying it is the biggest force transforming traditional models. However, despite all the hype, it ranks ninth out of the 10 value creation levers surveyed in how often it is used and how well it is implemented — indicating that many firms are still struggling to integrate AI into their operations efficiently.
Despite their potential to drive top-line growth, commercial levers remain among the least frequently used levers — with only 23% to 28% of firms reporting that they use levers like pricing optimization, AI and sales and marketing very often for value creation. Execution confidence also ranks among the lowest, signaling the complexity and resource demands of growth strategies.
'AI is no longer a futuristic concept — it's firmly on the agenda for private equity. But intent alone isn't enough,' said Lars Faeste, EMEA Chairman at FTI Consulting. 'We're seeing a clear gap between ambition and execution as firms wrestle with how to move from strategy to impact. The next phase of value creation isn't just about financial engineering or cost reduction — it's about disciplined execution in a more complex and unforgiving landscape. Success will come to the firms that translate innovation into outcomes, embedding technology and growth levers into how the business truly operates, scales and delivers value.'
Click here for more insights from the 2025 Private Equity Value Creation Index.
Demographics and MethodologyIn April 2025, FTI Consulting surveyed more than 500 decision makers at private equity firms, including investment professionals and operating partners, to understand the levers these firms use to create value in their portfolio companies. The survey included global participation from the United States, Latin America, Europe, the Middle East and Asia Pacific.
About FTI ConsultingFTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,100 employees located in 33 countries and territories as of March 31, 2025. In certain jurisdictions, FTI Consulting's services are provided through distinct legal entities that are separately capitalized and independently managed. The Company generated $3.70 billion in revenues during fiscal year 2024. More information can be found at www.fticonsulting.com.
FTI Consulting, Inc.555 12thStreet NWWashington, DC 20004+1.202.312.9100
Investor Contact:Mollie Hawkes+1.617.747.1791mollie.hawkes@fticonsulting.com
Media Contacts:Nick Emmons+1.617.747.1708nick.emmons@fticonsulting.com
Helen Obi+44 20 7632 5071helen.obi@fticonsulting.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 minutes ago
- Business Wire
OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) ('OS Therapies' or 'the Company'), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it received positive written feedback from the US Food & Drug Administration ('FDA') Type D Meeting that occurred in mid-June 2025 regarding endpoints required to support an Accelerated Approval Program marketing application for its Phase 2b trial of OST-HER2 in the prevention or delay of recurrence in fully resected, pediatric lung metastatic osteosarcoma. The Company reiterates that additional data from its Phase 2b trial will be presented at the major osteosarcoma conference MIB Factor in Salt Lake City on Saturday June 28, 2025 at 3:30pm MDT. Concurrent with this announcement, the Company announced that it has submitted End of Phase 2 Meeting and Breakthrough Therapy Designation (BTD) requests to FDA based on the positive Type D Meeting feedback. The End of Phase 2 Meeting is expected to occur in the third quarter of 2025. This is in alignment with the company's overall regulatory strategy and timelines. 'We are pleased with the feedback we received from the FDA regarding the use of external control comparators in settings where placebo-controlled randomization trials are not feasible – particularly in rare pediatric diseases such as the indication treated by OST-HER2 ,' said Dr. Robert Petit, Chief Medical & Scientific Officer of OS Therapies. 'Moreover, we received additional collaborative input regarding suggested statistical methods as we seek to compare OST-HER2 active treatment with external control arm(s) to support a Biologics Licensing Application (BLA) via the Accelerated Approval Program. Taken together, the feedback gives us insight on the FDA's current position and allows us to be fully prepared for the End of Phase 2 Meeting.' OST-HER2 has received Rare Pediatric Disease Designation (RPDD) for osteosarcoma from the US FDA, and if it receives a conditional BLA via Accelerated Review prior to September 30, 2026, it will become eligible to receive a Priority Review Voucher (PRV) that it intends to immediately sell. The most recent PRV sale occurred in June 2025, valued at $160 million. The osteosarcoma treatment market was estimated at $1.2 billion in 2022 according to Data Bridge Market Research. Approximately 50% of patients are diagnosed with a lung metastasis at some point following surgical resection and chemotherapy. 3-year survival rates in patients who were not diagnosed with a metastasis are 59%. 3-year survival rates in patients who were diagnosed with pulmonary metastasis were 30%. The Company believes the market opportunity for OST-HER2 in the prevention of lung metastases is over $500 million. OST-HER2, an immunotherapy for osteosarcoma that uses a HER2-bioengineered form of the bacterium Listeria monocytogenes to trigger a strong immune response against HER2-expressing cancer cells, is featured in the movie Shelter Me: The Cancer Pioneers. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people and covers developing treatments for rare forms of cancer. The movie is available via streaming on PBS' website. About OS Therapies OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA and European Medicines Agency. The Company positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and other risks and uncertainties described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Yahoo
6 minutes ago
- Yahoo
Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib
Company to host webcast and conference call on June 24, 2025 at 8:00am ET CAMBRIDGE, Mass., June 23, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the company will host a webcast and conference call on Tuesday, June 24, 2025 at 8:00 a.m. ET, to discuss pivotal data for zidesamtinib, a novel ROS1-selective inhibitor, in TKI pre-treated patients with advanced ROS1-positive non-small cell lung cancer from the global ARROS-1 Phase 1/2 clinical trial. Webcast and Conference Call Information To access the call, please dial +1 (800) 836-8184 (domestic) or +1 (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined to the Nuvalent call. Accompanying slides and a live video webcast will be available in the Investors section of the Nuvalent website at A replay and accompanying slides will be archived on the Nuvalent website for 30 days. About Zidesamtinib and the ARROS-1 Phase 1/2 Clinical Trial Zidesamtinib is a novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is designed to remain active in tumors that have developed resistance to currently available ROS1 inhibitors, including tumors with treatment-emergent ROS1 mutations such as G2032R. In addition, zidesamtinib is designed for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with dual TRK/ROS1 inhibitors and to drive deep, durable responses for patients across all lines of therapy. Zidesamtinib has received breakthrough therapy designation for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) who have been previously treated with 2 or more ROS1 tyrosine kinase inhibitors and orphan drug designation for ROS1-positive NSCLC. Zidesamtinib is currently being investigated in the ARROS-1 trial (NCT05118789), a first-in-human Phase 1/2 clinical trial for patients with advanced ROS1-positive NSCLC and other solid tumors. The completed Phase 1 portion enrolled ROS1-positive NSCLC patients who previously received at least one ROS1 TKI, or patients with other ROS1-positive solid tumors who had been previously treated. The Phase 1 portion of the trial was designed to evaluate the overall safety and tolerability of zidesamtinib, with additional objectives including determination of the recommended Phase 2 dose, characterization of the pharmacokinetic profile, and evaluation of preliminary anti-tumor activity. The ongoing global, single arm, open label Phase 2 portion is designed with registrational intent for TKI-naïve and TKI pre-treated patients with ROS1-positive NSCLC. About Nuvalent Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding Nuvalent's strategy, business plans, and focus; the expected timing of data announcements; the clinical development program for zidesamtinib; the design and enrollment of Nuvalent's clinical trials, including for ARROS-1 its intended pivotal registration-directed design the potential of Nuvalent's pipeline programs, including zidesamtinib; Nuvalent's research and development programs for the treatment of cancer; and risks and uncertainties associated with drug development. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "aim," "goal," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" or the negative of these terms and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. You should not place undue reliance on these statements or the scientific data presented. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: risks that Nuvalent may not fully enroll its clinical trials or that enrollment will take longer than expected; unexpected concerns that may arise from additional data, analysis, or results obtained during preclinical studies and clinical trials; the risk that preliminary results of clinical trials may not be predictive of future results from the same or other trials; the risk that results of earlier clinical trials may not be predictive of the results of later-stage clinical trials; the risk that data from our clinical trials may not be sufficient to support registration and that Nuvalent may be required to conduct one or more additional studies or trials prior to seeking registration of zidesamtinib; the occurrence of adverse safety events; risks that the FDA may not approve our potential products on the timelines we expect, or at all; risks of unexpected costs, delays, or other unexpected hurdles; risks that Nuvalent may not be able to nominate drug candidates from its discovery programs; the direct or indirect impact of public health emergencies or global geopolitical circumstances on the timing and anticipated timing and results of Nuvalent's clinical trials, strategy, and future operations, including the ARROS-1 trial; the timing and outcome of Nuvalent's planned interactions with regulatory authorities; and risks related to obtaining, maintaining, and protecting Nuvalent's intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Nuvalent's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as well as any prior and subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Nuvalent's views only as of today and should not be relied upon as representing its views as of any subsequent date. Nuvalent explicitly disclaims any obligation to update any forward-looking statements. View original content to download multimedia: SOURCE Nuvalent, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
V2X Industry Analysis, Trends, Size, Value Chain, and Regional Market Forecasts to 2032 Featuring Continental, NXP Semiconductors, Qualcomm Technologies, Bosch, HARMAN and Other Leading Players
Explore the booming global V2X market, projected to surge to USD 61.58 billion by 2032, at a CAGR of 44.71% Dublin, June 24, 2025 (GLOBE NEWSWIRE) -- The "V2X Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2032" has been added to offering. The global V2X market report offers a detailed qualitative and quantitative analysis from 2022 to 2032. Valued at USD 2.52 billion in 2023, the market is projected to surge to USD 61.58 billion by 2032, driven by a robust CAGR of 44.71% over the forecast period from 2024 to 2032. The report analyses key regions, including North America, Europe, Asia-Pacific, and Rest of the World (RoW). This extensive study presents a thorough examination of market drivers, restraints, opportunities, market size, forecasts, and emerging trends. The insights integrate findings from both primary and secondary research, offering an in-depth understanding of market dynamics. Using Porter's Five Forces Model, the report evaluates competitive rivalry, supplier and buyer influence, and new entrant opportunities between 2022 and 2032, while the growth matrix pinpoints investment areas for market players. The companies profiled in the report include: Continental AG NXP Semiconductors Qualcomm Technologies, Inc. Robert Bosch GmbH HARMAN International Cisco Systems, Inc. Infineon Technologies AG Autotalks DENSO CORPORATION Cohda Wireless Key Report Insights Drivers Increasing demand for advanced vehicle safety technologies is fueling market growth. The rising interest in smart vehicles is further propelling the V2X market expansion. Restraints Data security concerns present challenges to market growth. Opportunities The adoption of C-V2C and AI technologies promises lucrative growth opportunities. Report Highlights Exhaustive global and regional market analysis. In-depth coverage of all market segments with emerging trends and forecast analysis until 2032. Detailed company profiles showcasing product portfolios, SWOT analysis, and recent developments. Growth Matrix analysis sheds light on viable product segments and geographical investment opportunities for market players. Key Topics CoveredChapter 1. Preface1.1. Report Description1.2. Research Methods1.3. Research ApproachesChapter 2. Executive Summary2.1. V2X Market Highlights2.2. V2X Market Projection2.3. V2X Market Regional HighlightsChapter 3. Global V2X Market Overview3.1. Introduction3.2. Market Dynamics3.3. Porter's Five Forces Analysis3.4. Growth Matrix Analysis3.5. Value Chain Analysis of V2X MarketChapter 4. V2X Market Macro Indicator AnalysisChapter 5. Company Profiles and Competitive Landscape5.1. Competitive Landscape in the Global V2X Market5.2. Companies ProfilesChapter 6. Global V2X Market by ComponentChapter 7. Global V2X Market by Communication TypeChapter 8. Global V2X Market by Connectivity TypeChapter 9. Global V2X Market by Vehicle TypeChapter 10. Global V2X Market by Region 2024-203210.1. North America10.2. Europe10.3. Asia-Pacific10.4. RoW For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Connectez-vous pour accéder à votre portefeuille
